- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
A child’s chance to survive and thrive is much greater in 2015 than it was when the global community committed to the MDGs in 2000.
Data show significant progress in areas such as child survival, nutrition, motherto- child transmission of HIV and primary school enrolment, among others. These are impressive achievements, but they are only part of the story.
This report also shows progress for the most vulnerable, proving that a more equitable world is within reach. But despite this progress, millions of the children in greatest need have been left behind – the most marginalized and vulnerable children whose future the MDGs were designed to safeguard.
Keywords: children, gender equality, child mortality, infants, maternal health
In this brief, we review drug pricing for new hepatitis C medications and pose basic questions of fairness and medical ethics. Although we focus on Gilead and its hepatitis C drug sofosbuvir, the issues we highlight are broadly applicable to other manufacturers of hepatitis C medications.
Viet Nam has committed to working towards the elimination of HIV mother-to-child transmission. The stated goals are to reduce the vertical transmission rate of HIV nationally to less than 5% by 2015 and to less than 2% by 2020.
Viet Nam has high hepatitis B virus (HBV) and low HIV and syphilis prevalence among pregnant women. Antenatal care (ANC) coverage is high (one visit 96,6%, three visits 87.5%)*. Prevention of mother-to-child-transmission (PMTCT) of HIV and infant hepatitis B immunization are managed by separate vertical programmes and services. It is national policy that free provider-initiated universal HIV testing is recommended to pregnant women (PW). Syphilis and hepatitis B testing are not routinely offered. This study aims at demonstrating an innovative model of combined universal screening for HIV, syphilis, and HBV for PW and treatment of infected PW in ANC to prevent vertical transmission of three infections.
Antimicrobial resistance threatens the very core of modern medicine and the sustainability of an effective, global public health response to the enduring threat from infectious diseases. Systematic misuse and overuse of these drugs in human medicine and food production have put every nation at risk. Few replacement products are in the pipeline. Without harmonized and immediate action on a global scale, the world is heading towards a post-antibiotic era in which common infections could once again kill.
Surveillance of transmitted HIV drug resistance (TDR) in individuals recently infected with HIV was performed following WHO-suggested methods. The prevalence of transmitted HIV drug resistance (TDR) in recently infected antiretroviral drug naïve individuals in PNG has not been fully characterised.
This document presents experiences of how community-based antiretroviral therapy (ART) delivery can improve both the level of access to treatment and the quality of health outcomes for people living with HIV. These experiences illustrate that community-based ART delivery is efficient, effective and high quality.
UNAIDS welcomes additional evidence released in May 2015 that early initiation of antiretroviral therapy has a positive effect on the health and well-being of people living with HIV. The United States National Institutes of Health-funded international randomized clinical trial START (Strategic Timing of Antiretroviral Treatment) has found compelling evidence that the benefits of starting antiretroviral therapy as soon as someone is diagnosed outweigh the risks of delaying until their CD4 count has fallen to 350 cells/mm3.
This report describes the current continuum of testing for HCV, which is complex and expensive, which means that it is very challenging to implement in resource-limited settings. It examines the platforms/tests that are currently available across the range of required HCV testing from screening to confirmation and genotyping, fibrosis staging and treatment monitoring. The report also considers how the testing cascade for HCV may be simplified with the availability of DAAs, which would help make HCV testing attainable in resource-limited settings. Finally, it looks at the pipeline of tests/platforms for HCV that could be delivered at or near the point of patient care.
Keywords: HIV, HCV, treatment, testing, monitoring
A survey was conducted in countries in all six WHO regions and focused on the building blocks that are considered prerequisites to combat antimicrobial resistance: a comprehensive national plan, laboratory capacity to undertake surveillance for resistant microorganisms, access to safe, effective antimicrobial medicines, control of the misuse of these medicines, awareness and understanding among the general public and effective infection prevention and control programmes.
The world faces an important window of opportunity in the trajectory of the global AIDS response. New scientific evidence shows that starting HIV treatment immediately upon diagnosis enables people to live longer, healthier lives and is among the most effective ways to prevent HIV transmission. Several years ago, in response to this evidence, some countries began providing all people living with HIV access to immediate treatment.